Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Bmy crawled time : 14:00 save search
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Published: 2024-02-26 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.19%
H: 0.23%
C: -2.02%
acquisition platform
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
Published: 2024-01-17 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.9%
H: 1.05%
C: 0.87%
asco treatment research
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
Published: 2024-01-02 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.27%
H: 3.89%
C: 2.55%
lung tumors cancer cell treatment application advanced
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
Published: 2023-09-26 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.49%
H: 0.65%
C: -0.56%
therapeutics milestone
Myasthenia Gravis Treatment Market to Grow Exponentially by 2029 | Brandessence Market Research
Published: 2023-09-18 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 2.7%
H: 0.0%
C: -5.11%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.72%
H: 0.13%
C: -0.93%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: 0.06%
H: 0.44%
C: -0.64%
treatment research market
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
Published: 2023-09-14 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.42%
H: 0.36%
C: -0.57%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.82%
H: 0.68%
C: -1.08%
day pipeline research growth
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-11 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.12%
H: 1.11%
C: 0.1%
lung opdivo cancer cell treatment trial plus show
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
Published: 2023-08-28 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.03%
H: 0.56%
C: -0.68%
partnership cell car-t program technology therapy platform
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
Published: 2023-05-01 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.76%
H: 2.17%
C: 1.66%
IMTX | $10.15 -2.59% -2.66% 220K
|
Health Technology
|
| O: 1.26%
H: 3.38%
C: 1.1%
candidate ongoing collaboration
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Published: 2023-03-09 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.1%
H: 0.31%
C: -3.32%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.46%
H: 0.18%
C: -1.61%
revlimid teva
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
Published: 2023-03-07 (Crawled : 14:00) - globenewswire.com
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -1.71%
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 3.82%
H: 1.23%
C: -4.91%
positive cancer publication ovarian cancer
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
Published: 2023-03-03 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.25%
H: 0.09%
C: -0.09%
reblozyl anemia approval
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.54%
H: 0.67%
C: 0.46%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.06%
collaboration program trial
Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.27%
H: 0.2%
C: -1.2%
care conference health
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: 0.16%
H: 0.17%
C: -0.43%
cardiovascular cardiology
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.23%
H: 0.09%
C: -0.39%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.2%
H: 0.66%
C: 0.6%
WBA 4 | $17.82 -1.27% -1.29% 10M
|
Retail Trade
|
| O: 1.36%
H: 0.24%
C: -0.22%
GERN | $3.58 2.29% 1.96% 5.7M
|
Health Technology
|
| O: -0.91%
H: 3.36%
C: 0.92%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.76%
H: 0.32%
C: -1.11%
commercial
Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.26%
H: 1.68%
C: 0.7%
conference
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.26%
H: 1.68%
C: 0.7%
Envisagenics Announces Research Collaboration with Bristol Myers Squibb
Published: 2022-11-29 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.42%
H: 0.38%
C: 0.28%
research collaboration
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.